Previous close | 1,401.20 |
Open | 1,401.45 |
Bid | 1,418.80 x 0 |
Ask | 1,419.90 x 0 |
Day's range | 1,399.30 - 1,425.75 |
52-week range | 897.70 - 1,519.00 |
Volume | |
Avg. volume | 31,740 |
Market cap | 1.146T |
Beta (5Y monthly) | 0.37 |
PE ratio (TTM) | 30.89 |
EPS (TTM) | 45.96 |
Earnings date | 10 May 2024 |
Forward dividend & yield | 8.50 (0.61%) |
Ex-dividend date | 21 Jul 2023 |
1y target est | N/A |
Indian drugmakers aiming to grab a slice of the burgeoning weight-loss treatment sales pie, both at home and abroad, have begun developing their own versions of Novo Nordisk's wildly in demand Wegovy. With some analysts predicting a weight-loss market reaching $100 billion a year or more by the end of the decade, executives at Sun Pharma, Cipla, Dr Reddy's and Lupin -- some of the world's largest generic drugmakers -- all said they have started work on Wegovy versions. Novo Nordisk has been unable to produce enough Wegovy to meet demand in more than half a dozen countries where it has already launched, amid record global obesity rates and people looking for easier alternatives to diet and exercise.
Cipla (EU) Limited, UK a wholly owned subsidiary of Cipla Limited (BSE:500087; NSE: Cipla EQ], hereinafter referred to as Cipla has announced a strategic collaboration with Kemwell Biopharma Private Limited (through its subsidiary Kemwell Biopharma UK Limited) and Manipal Education & Medical Group (through its subsidiary MNI Ventures, Mauritius) to incorporate a joint venture in the United States. The primary goal of this joint venture is to develop and commercialise novel Cell therapy products
India's benchmark indexes on Thursday closed at a two-week low in a broad-based selloff, after the U.S. Federal Reserve signalled that interest rates will remain elevated for longer. The Nifty 50 closed 0.8% lower at 19,742.35 points, its lowest close since Sept.7, while the S&P BSE Sensex declined about 0.85% to 66,230.24 points. The Fed on Wednesday held key interest rates unchanged as widely expected, but warned that the battle against inflation was far from over.